pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Linear regression analysis of blood glucose changes during pembrolizumab administration for (A) all patients and (B) patients of no history of diabetes and concomitant therapy

(A) Characteristics for overall patients (N=133) Slope p-value
Total patients -0.057 0.563
Sex Male -0.032 0.793
Female -0.152 0.264
BMI, kg/m2 (categorized) Underweight (<18.5) -0.179 0.359
Normal (≥18.5, <23) -0.086 0.488
Overweight (≥23, <25) 0.141 0.595
Obese (≥25) -0.124 0.569
Baseline blood glucose, ml/dl < 130 0.075 0.167
≥ 130 -0.269 0.158
History of Diabetes Yes -0.024 0.934
No -0.083 0.271
Treatment of diabetes Yes 0.092 0.784
No -0.094 0.188
Concomitant steroid therapy No -0.117 0.364
Yes 0.032 0.838
Concomitant steroid therapy categorized by administration purpose Prophylactic 0.072 0.557
Intervention -0.042 0.883
(B) Characteristics for subgroup patients (N=62, no history of diabetes and concomitant therapy)
Total patients -0.100 0.180
Sex Male -0.119 0.148
Female -0.035 0.848
BMI, kg/m2 (categorized) Underweight (<18.5) 0.170 0.552
Normal (≥18.5, <23) -0.135 0.175
Overweight (≥23, <25) -0.068 0.705
Obese (≥25) -0.185 0.251
Baseline blood glucose, ml/dl (categorized) < 130 0.111 0.157
≥ 130 -0.548 < 0.001
Korean J Clin Pharm 2021;31:237-46 https://doi.org/10.24304/kjcp.2021.31.3.237
© 2021 Korean J Clin Pharm